National Institute for Health and Care Excellence. Menopause: clinical guideline – methods, evidence and recommendations (NG23), version 1.5 www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261 (accessed 12 November 2015). For Tables 1 and 2 see pp. 151–152.
2.
BoardmanHMPHartleyLEisingaA. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev2015; 4: CD002229.
3.
SalpeterSRWalshJMEGreyberE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med2006; 21: 363–366.
4.
SchierbeckLLRejnmarkLToftengCL. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J2012; 345: e6409.
5.
MansonJEChlebowskiRTStefanickML. Menopausal hormone therapy and health outcomes during the interventions and postintervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA2013; 310: 1353–1368.
6.
TuomikoskiPLyytinenHKorhonenP. Coronary heart disease mortality and hormone therapy before and after the Women’s Health Initiative. Obstet Gynecol2014; 124: 947–953.
7.
StevensonJCHRT and cardiovascular disease. In: LumsdenMA (ed.). Best practice and research clinical obstetrics and gynaecology, vol. 23, Elsevier, 2009, pp. 109–120.
8.
LokkegardEJovanovicZHeitmannBL. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas2006; 53: 226–233.
9.
MikkolaTTuomikoskiPLyytinenH. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab2015; 100: 4588–4594.
